Accretion Pharmaceuticals MD, chairman and AGM

Accretion Pharmaceuticals board of directors

At the end of the quarter to Sep 2026, as the company filed it; changes since are in its announcements.

An independent director has no business or family tie to the company, its promoters or its managers beyond the seat. Listed boards counts the boards of listed companies the director sits on, this one included, and "as independent" how many of those seats are independent ones. Committee seats are audit and stakeholder committee seats across those companies. Months as independent is filed for independent directors only, whose terms the rules cap. Disqualified is the company's own mark that a director may not serve under company law.

Statutory auditor

Named in the results for the quarter to Mar 2025.

V S S B & AssociatesPeer-review certificate valid to Oct 2026

A statutory auditor checks the company's accounts and signs its results. Peer review is the accountants' institute's check of an audit firm's own work, which a listed company's auditor must hold a valid certificate of.

Accretion Pharmaceuticals AGM and shareholder votes

Each resolution, how the votes went, and how institutions voted apart from the promoters. A postal ballot is a vote by post or online, held without a meeting.Accretion Pharmaceuticals share news and announcements

Postal ballot, 9 Oct 2026

732 shareholders on the register on 4 Sep 2026; votes counted by CS Nimish Sakhiya / M/s. Sakhiya & Co..The company's voting result (opens in a new tab)

Approval for alteration of the Memorandum of Association of the Company.
Special
100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 74.27% · promoters 100.00% · institutions 0.00% · other public 3.35%
Approval for the increase in borrowing limits of the Company under section 180(1)(c) of the Companies Act, 2013.
Special
100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 74.27% · promoters 100.00% · institutions 0.00% · other public 3.35%
Approval for the creation of mortgage/ charge on the properties/ undertakings of the Company under section 180(1)(a) of the Companies Act, 2013.
Special
100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 74.27% · promoters 100.00% · institutions 0.00% · other public 3.35%
Approval for revised limits of advancing loan(s), giving any guarantee(s) and/or to providing any security (ies) to the subsidiary (ies) of the Company under section 185 of Companies act, 2013.
SpecialPromoters have an interest in it
100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 0.76% · promoters 0.00% · institutions 0.00% · other public 3.35%
Approval for the limit for the loan, guarantee and investment by the Company under section 186 of the Companies Act, 2013.
Special
100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 74.27% · promoters 100.00% · institutions 0.00% · other public 3.35%

For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.

Annual general meeting, 27 Aug 2026, 2 resolutions

746 shareholders on the register on 20 Aug 2026; present: 8 promoters and 6 others; votes counted by CS Nimish Sakhiya / M/s. Sakhiya & Co..The company's voting result (opens in a new tab)

To receive, consider and adopt the Standalone Financial Statements as at 31 March, 2026 including the Audited Balance Sheet as at 31 March, 2026, the Statement of Profit and Loss for the year ended on that date and reports of the Board of Directors and Auditors thereonMoreLess
Ordinary
100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 77.09% · promoters 100.00% · institutions 0.00% · other public 15.85%
To appoint a director in place of Mr. Hardik Mukundbhai Prajapati (DIN: 09108403), Director, who retires by rotation and being eligible, offers himself for re-appointment
Ordinary
100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 58.72% · promoters 75.01% · institutions 0.00% · other public 15.85%

For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.

Dealings with its subsidiaries, promoters, directors and their firms, reported every half-year.Promoters and their stake

Half-year to Mar 2026: ₹1.93 Cr18 dealings
Half-year to Sep 2025: ₹0.89 Cr16 dealings
Half-year to Mar 2025: ₹2.65 Cr13 dealings

Between	Dealing
Accretion Pharmaceuticals Limited and Accresha Lifecare Private LimitedDirectors having Significant Influence and Others	Sale of goods or services	10.00	0.93	0.01	0.32
Accretion Pharmaceuticals Limited and Accretion Nutraveda LimitedDirectors having Significant Influence and Others	Purchase of goods or services	5.00	0.32	0.03	0.00
Accretion Pharmaceuticals Limited and Mr. Hardik Mukundbhai PrajapatiDirector	Remuneration	0.50	0.15	0.00	0.02
Accretion Pharmaceuticals Limited and Mr. Harshad Nanubhai RathodDirector and Key Management Personnel	Remuneration	0.50	0.15	0.00	0.02
Accretion Pharmaceuticals Limited and Mr. Vivek Ashok Kumar PatelDirector and Key Management Personnel	Remuneration	0.50	0.15	0.00	0.02
Accretion Pharmaceuticals Limited and Mr. Mayur Popatlal SojitraDirector	Remuneration	0.50	0.15	0.00	0.02
Accretion Pharmaceuticals Limited and Mrs. Hiral Dipen ShahPart of Promoter Group	Any other transactionSalary	0.08	0.06	0.00	₹47,000
Accretion Pharmaceuticals Limited and Accretion INCDirectors having Significant Influence and Others	Sale of goods or services	0.50	0.03	0.00	0.00
Accretion Pharmaceuticals Limited and Mrs. Ankita Vivek PatelPart of Promoter Group	Any other transactionAvailing Services	0.02	₹80,000	0.00	0.00
Accretion Pharmaceuticals Limited and Accretion Nutraveda LimitedDirectors having Significant Influence and Others	Sale of goods or services	5.00	₹5,000	0.00	0.00
Accretion Pharmaceuticals Limited and Accresha Lifecare Private LimitedDirectors having Significant Influence and Others	Any other transactionAdvances / Trade payables	5.00	0.00	0.00	0.00
Accretion Pharmaceuticals Limited and Accretion Nutraveda LimitedDirectors having Significant Influence and Others	Any other transactionAdvances / Trade receivables	5.00	0.00	0.00	0.00
Accretion Pharmaceuticals Limited and Accretion Nutraveda LimitedDirectors having Significant Influence and Others	Any other transactionAdvances / Trade payables	5.00	0.00	0.00	0.00
Accretion Pharmaceuticals Limited and Accretion INCDirectors having Significant Influence and Others	Purchase of goods or services	0.50	0.00	0.00	0.00
Accretion Pharmaceuticals Limited and Accretion INCDirectors having Significant Influence and Others	Any other transactionAdvances / Trade receivables	0.10	0.00	0.00	0.00
Accretion Pharmaceuticals Limited and Accretion INCDirectors having Significant Influence and Others	Any other transactionAdvances / Trade payables	0.10	0.00	0.00	0.00
Accretion Pharmaceuticals Limited and Accresha Lifecare Private LimitedDirectors having Significant Influence and Others	Purchase of goods or services	5.00	0.00	0.00	0.00
Accretion Pharmaceuticals Limited and Accresha Lifecare Private LimitedDirectors having Significant Influence and Others	Any other transactionAdvances / Trade receivables	5.00	0.00	0.00	0.00

The 18 largest of 18 dealings in the half-year to Mar 2026, ₹ crore.

Investor complaints and compliance

Quarter by quarter.

Investor complaints received and resolved, the company's own count

Received
Resolved

Open at the quarter's end

None open at any quarter's end.

The filing has a part on fines and penalties: No
The filing has a part on tax disputes: No

The company's own answers in its filing.

How money raised was used

Reported for the quarter to Mar 2026.

Raised	Amount raised	For	Set aside	Spent	Spent elsewhere
Public IssuesMay 2025	29.75	Capital expenditure towards purchase of new equipment/ machineries, etc.	2.70	2.70	No
Public IssuesMay 2025	29.75	Capital expenditure towards upgradation of existing manufacturing facility	4.66	4.66	No
Public IssuesMay 2025	29.75	Repayment/prepayment of certain borrowings availed by our Company	0.99	0.99	No
Public IssuesMay 2025	29.75	Funding working capital requirements	14.68	14.68	No
Public IssuesMay 2025	29.75	General Corporate Purpose	4.43	4.43	No
Public IssuesMay 2025	29.75	IPO related expenses	2.30	2.30	No

₹ crore. Checked by is the agency appointed to monitor how the money is used. The reason and the comments are the company's, its audit committee's and its auditors' own words.